Nanoliposomal Nitroglycerin Exerts Potent Anti-Inflammatory Effects

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Ardekani, Soroush ^a   Scott, Harry A ^a   Gupta, Sharad ^b,d   Eum, Shane ^a   Yang, Xiao ^a   Brunelle, Alexander R ^c   Wilson, Sean M ^c   Mohideen, Umar ^b   Ghosh, Kaustabh ^a  

^a University of California Riverside   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INDIAN INSTITUTE OF TECHNOLOGY INDORE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; GLYCERYL TRINITRATE; INTERCELLULAR ADHESION MOLECULE 1; LIPOSOME; NANOPARTICLE; NITRIC OXIDE; SUPEROXIDE;

ANIMAL; CELL ADHESION; CELL LINE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ENDOTHELIUM CELL; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; METABOLISM; MITOCHONDRION; MONOCYTE; PHYSIOLOGY; PREGNANCY; PULMONARY ARTERY; SCANNING ELECTRON MICROSCOPY; SHEEP; U-937 CELL LINE; ULTRASTRUCTURE; VASODILATATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL ADHESION; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LIPOSOMES; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, FLUORESCENCE; MITOCHONDRIA; MONOCYTES; NANOPARTICLES; NITRIC OXIDE; NITROGLYCERIN; PREGNANCY; PULMONARY ARTERY; SHEEP; SUPEROXIDES; U937 CELLS; VASODILATION;

EID: 84947765413     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16258     Document Type: Article

References (36)

1. Rabinovitch, M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 122, 4306-4313, doi: 10.1172/JCI60658 (2012).
2. Tousoulis, D., Kampoli, A. M., Tentolouris, C., Papageorgiou, N. & Stefanadis, C. The role of nitric oxide on endothelial function. Curr Vasc Pharmacol 10, 4-18 (2012).
3. Zhang, Y. X., Janssens, S. P., Wingler, K., Schmidt, H. H. H. W. & Moens, A. L. Modulating endothelial nitric oxide synthase: a new cardiovascular therapeutic strategy. Am J Physiol-Heart C 301, H634-H646, doi: 10.1152/Ajpheart.01315.2010 (2011).
4. Stokes, K. Y. et al. Dietary nitrite prevents hypercholesterolemic microvascular inflammation and reverses endothelial dysfunction. Am J Physiol-Heart C 296, H1281-H1288, doi: 10.1152/Ajpheart.01291.2008 (2009).
5. Herman, A. G. & Moncada, S. Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis. Eur Heart J 26, 1945-1955, doi: 10.1093/eurheartj/ehi333 (2005).
6. Omar, S. A., Artime, E. & Webb, A. J. A comparison of organic and inorganic nitrates/nitrites. Nitric Oxide 26, 229-240, doi: 10.1016/j.niox.2012.03.008 (2012).
7. Chen, Z., Zhang, J. & Stamler, J. S. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USA 99, 8306-8311, doi: 10.1073/pnas.122225199 (2002).
8. Bonini, M. G. et al. Constitutive nitric oxide synthase activation is a significant route for nitroglycerin-mediated vasodilation. Proc Natl Acad Sci USA 105, 8569-8574, doi: 10.1073/pnas.0708615105 (2008).
9. Mao, M. et al. Nitroglycerin drives endothelial nitric oxide synthase activation via the phosphatidylinositol 3-kinase/protein kinase B pathway. Free Radic Biol Med 52, 427-435, doi: 10.1016/j.freeradbiomed.2011.09.020 (2012).
10. Sydow, K. et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest 113, 482-489, doi: 10.1172/JCI19267 (2004).
11. Daiber, A. et al. Mitochondrial aldehyde dehydrogenase (ALDH-2)-maker of and marker for nitrate tolerance in response to nitroglycerin treatment. Chem Biol Interact 178, 40-47, doi: 10.1016/j.cbi.2008.09.003 (2009).
12. Daiber, A. et al. Oxidative stress and mitochondrial aldehyde dehydrogenase activity: A comparison of pentaerythritol tetranitrate with other organic nitrates. Mol Pharmacol 66, 1372-1382, doi: 10.1124/Mol.104.002600 (2004).
13. Farokhzad, O. C. & Langer, R. Impact of nanotechnology on drug delivery. ACS nano 3, 16-20, doi: 10.1021/nn900002m (2009).
14. Shi, J., Votruba, A. R., Farokhzad, O. C. & Langer, R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett 10, 3223-3230, doi: 10.1021/nl102184c (2010).
15. Ghosh, K., Kanapathipillai, M., Korin, N., McCarthy, J. R. & Ingber, D. E. Polymeric nanomaterials for islet targeting and immunotherapeutic delivery. Nano Lett 12, 203-208, doi: 10.1021/nl203334c (2012).
16. Yoshizumi, M., Perrella, M. A., Burnett, J. C., Jr. & Lee, M. E. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circulation research 73, 205-209 (1993).
17. Bouzin, C., Brouet, A., De Vriese, J., DeWever, J. & Feron, O. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: Identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J Immunol 178, 1505-1511 (2007).
18. Decaterina, R. et al. Nitric-Oxide Decreases Cytokine-Induced Endothelial Activation - Nitric-Oxide Selectively Reduces Endothelial Expression of Adhesion Molecules and Proinflammatory Cytokines. J Clin Invest 96, 60-68, doi: 10.1172/Jci118074 (1995).
19. Parker, J. D. & Parker, J. O. Nitrate therapy for stable angina pectoris. New Engl J Med 338, 520-531 (1998).
20. Uxa, A., Thomas, G. R., Gori, T. & Parker, J. D. Standard versus low-dose transdermal nitroglycerin: differential effects on the development of tolerance and abnormalities of endothelial function. J Cardiovasc Pharmacol 56, 354-359, doi: 10.1097/FJC.0b013e3181ed2dae (2010).
21. Liuni, A. et al. Coadministration of atorvastatin prevents nitroglycerin-induced endothelial dysfunction and nitrate tolerance in healthy humans. Journal of the American College of Cardiology 57, 93-98, doi: 10.1016/j.jacc.2010.07.037 (2011).
22. Peschka, R., Dennehy, C. & Szoka, F. C., Jr. A simple in vitro model to study the release kinetics of liposome encapsulated material. J Control Release 56, 41-51 (1998).
23. Knorr, M. et al. Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-Glutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan. Arteriosclerosis, thrombosis, and vascular biology 31, 2223-2231, doi: 10.1161/ATVBAHA.111.232058 (2011).
24. Nie, S. D. et al. Reversal of tolerance to nitroglycerin with vinpocetine: A role of calcitonin gene-related peptide. Int J Cardiol 125, 436-438, doi: 10.1016/J.Ijcard.2007.06.041 (2008).
25. Pober, J. S. & Sessa, W. C. Evolving functions of endothelial cells in inflammation. Nature Reviews Immunology 7, 803-815, doi: 10.1038/Nri2171 (2007).
26. Schnoor, M. Endothelial actin-binding proteins and actin dynamics in leukocyte transendothelial migration. J Immunol 194, 3535-3541, doi: 10.4049/jimmunol.1403250 (2015).
27. Loirand, G. & Pacaud, P. The role of Rho protein signaling in hypertension. Nature reviews. Cardiology 7, 637-647, doi: 10.1038/nrcardio.2010.136 (2010).
28. Wojciak-Stothard, B., Williams, L. & Ridley, A. J. Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering. The Journal of cell biology 145, 1293-1307 (1999).
29. Cotechini, T., Othman, M. & Graham, C. H. Nitroglycerin prevents coagulopathies and foetal death associated with abnormal maternal inflammation in rats. Thromb Haemost 107, 864-874, doi: 10.1160/TH11-10-0730 (2012).
30. Katzung, M. S. B. & Trevor, A. J. in Basic and Clinical Pharmacology 12th edn, Ch. 12, 195-196 (McGraw-Hill, 2007).
31. Muzykantov, R. V. Targeted Drug, Delivery to Endothelial Adhesion Molecules. ISRN Vascular Medicine 2013, 1-27, doi: 10.1155/2013/916254 (2013).
32. Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery 4, 145-160, doi: 10.1038/Nrd1632 (2005).
33. Immordino, M. L., Dosio, F. & Cattel, L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1, 297-315 (2006).
34. Kolhar, P. et al. Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. Proc Natl Acad Sci USA 110, 10753-10758, doi: 10.1073/Pnas.1308345110 (2013).
35. Voelkel, N. F., Gomez-Arroyo, J., Abbate, A., Bogaard, H. J. & Nicolls, M. R. Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J 40, 1555-1565, doi: 10.1183/09031936.00046612 (2012).
36. Ades, E. W. et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 99, 683-690 (1992).